AveXis, Inc. (AVXS) EPS Estimated At $-1.51

February 23, 2018 - By Dolores Ford

 AveXis, Inc. (AVXS) EPS Estimated At $ 1.51

Analysts expect AveXis, Inc. (NASDAQ:AVXS) to report $-1.51 EPS on March, 15.They anticipate $0.59 EPS change or 64.13 % from last quarter’s $-0.92 EPS. After having $-1.52 EPS previously, AveXis, Inc.’s analysts see -0.66 % EPS growth. The stock increased 2.43% or $2.83 during the last trading session, reaching $119.53. About 349,210 shares traded. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since February 23, 2017 and is uptrending. It has outperformed by 79.15% the S&P500.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. The firm earned “Market Perform” rating on Friday, July 15 by Wells Fargo. Goldman Sachs maintained AveXis, Inc. (NASDAQ:AVXS) rating on Friday, May 13. Goldman Sachs has “Buy” rating and $47 target. The company was upgraded on Friday, August 12 by Jefferies. The rating was initiated by Bank of America with “Buy” on Friday, October 21. The firm has “Buy” rating by Jefferies given on Monday, September 19.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $4.36 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

More news for AveXis, Inc. (NASDAQ:AVXS) were recently published by: Globenewswire.com, which released: “AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS …” on January 30, 2018. Globenewswire.com‘s article titled: “AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results” and published on February 20, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: